Kymera Therapeutics Inc (KYMR) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Kymera Therapeutics Inc

NASDAQ | KYMR

23.69

USD

-2.67 (-10.13%)

AT CLOSE (AS OF Apr 3, 2025)

$1.7B

MARKET CAP

P/E Ratio

-2.98

EPS

$53

52 Week High

$24

52 Week Low

LIFE SCIENCES

Sector

KYMR Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

KYMR Technicals

Tags:

KYMR Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$22M
Total Revenue	$78M
Cost Of Revenue	$57M
Costof Goods And Services Sold	$189M
Operating Income	-$166M
Selling General And Administrative	$55M
Research And Development	$189M
Operating Expenses	$244M
Investment Income Net	-
Net Interest Income	-$181K
Interest Income	$19M
Interest Expense	$181K
Non Interest Income	$79M
Other Non Operating Income	$19M
Depreciation	$3.6M
Depreciation And Amortization	$1.5M
Income Before Tax	-$147M
Income Tax Expense	$19M
Interest And Debt Expense	$181K
Net Income From Continuing Operations	-$147M
Comprehensive Income Net Of Tax	-$143M
Ebit	-$166M
Ebitda	-$164M
Net Income	-$147M

Revenue & Profitability

Earnings Performance

KYMR Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$576M
Total Current Assets	$405M
Cash And Cash Equivalents At Carrying Value	$110M
Cash And Short Term Investments	$375M
Inventory	$1
Current Net Receivables	$15M
Total Non Current Assets	$170M
Property Plant Equipment	$48M
Accumulated Depreciation Amortization Ppe	$10M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$326M
Long Term Investments	$61M
Short Term Investments	$265M
Other Current Assets	$12M
Other Non Current Assets	$2.1M
Total Liabilities	$181M
Total Current Liabilities	$86M
Current Accounts Payable	$7.1M
Deferred Revenue	$109M
Current Debt	$1.3M
Short Term Debt	$6.3M
Total Non Current Liabilities	$95M
Capital Lease Obligations	$1.3M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$85M
Other Current Liabilities	$524K
Other Non Current Liabilities	$0
Total Shareholder Equity	$395M
Treasury Stock	-
Retained Earnings	-$531M
Common Stock	$6K
Common Stock Shares Outstanding	$59M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$103M
Payments For Operating Activities	$1.5M
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$3.4M
Change In Operating Assets	$16M
Depreciation Depletion And Amortization	$3.6M
Capital Expenditures	$34M
Change In Receivables	$15M
Change In Inventory	$23M
Profit Loss	-$147M
Cashflow From Investment	$140M
Cashflow From Financing	$4.2M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	$0
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$4.3M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$147M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$22M
Total Revenue	$78M
Cost Of Revenue	$57M
Costof Goods And Services Sold	$189M
Operating Income	-$166M
Selling General And Administrative	$55M
Research And Development	$189M
Operating Expenses	$244M
Investment Income Net	-
Net Interest Income	-$181K
Interest Income	$19M
Interest Expense	$181K
Non Interest Income	$79M
Other Non Operating Income	$19M
Depreciation	$3.6M
Depreciation And Amortization	$1.5M
Income Before Tax	-$147M
Income Tax Expense	$19M
Interest And Debt Expense	$181K
Net Income From Continuing Operations	-$147M
Comprehensive Income Net Of Tax	-$143M
Ebit	-$166M
Ebitda	-$164M
Net Income	-$147M

KYMR Profile

Kymera Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

KYMR $23.69 (-10.13%) Quote details